NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) will participate in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) will participate in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. CEO Alex Zwyer is scheduled for a live interview on September 29 from 1:55 PM to 2:15 PM ET. Attendees can access the interview here, with a replay available on the company website. NLS focuses on developing therapies for rare CNS disorders and is advancing its lead candidate, Quilience, for narcolepsy, which has Orphan Drug Designations in the U.S. and Europe.
Details
News Market Reaction – NLSP
The recorded move for NLSP in the trading session of this news was +1.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to participate in a live interview and meet with investors at the Benzinga Healthcare Small Cap Conference to be held virtually on September 29-30, 2021.
Event Details:
Date: September 29, 2021
Time: 1:55pm - 2:15pm ET
Event Access: Please click this link to access the live interview. A replay will also be available on the Company's website at https://nls-pharma.com/
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS has recently initiated a phase 2 study in the U.S. evaluating Quilience® in adult subjects suffering from Narcolepsy. Previously, NLS successfully completed a phase 2 study in the U.S. evaluating Nolazol® (mazindol controlled-release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3rd of narcoleptic patients are also diagnosed with ADHD.
Corporate Contact
Alex Zwyer, CEO
+41 41 618 80 00
Investor Relations Contact
Cindy Rizzo
+1 908-229-7050
www.nlspharma.com
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/665344/NLS-Pharmaceutics-to-Participate-in-the-Benzinga-Healthcare-Small-Cap-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.